Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.

Brittany BychkovskyAlison LawsFisher KatlinMarybeth HansMary Knust GraichenLydia E PaceRochelle ScheibJudy E GarberTari A King

Published in: Breast cancer research and treatment (2022)

In this modern cohort, 22.7% of females with HRLs initiated chemoprevention with 31.0% initiating chemoprevention > 6 months after their first visit. Low-dose tamoxifen is now the most popular choice for chemoprevention, with low discontinuation rates at 1 year.

Keyphrases

low dose
high dose
breast cancer cells
estrogen receptor
positive breast cancer
risk assessment
climate change